New Vaccine Combo for Kids Approved


The FDA approved a new vaccine combination that could mean one shot fewer for children getting their recommended routine vaccinations.

The US Food and Drug Administration (FDA) has approved a new vaccine combination to immunize children ages 4 through 6 against diphtheria, tetanus, pertussis and poliomyelitis.The new DTaP-IPV vaccine (Quadracel/Sanofi Pasteur) potentially reduces the number of routine vaccinations children will be recommended to receive, the company said in announcing the approval.

Sanofi said a getting a single dose of Quadracel has been approved as a fifth dose in the DTaP series and as a fourth or fifth dose in inactivated poliovirus vaccination series in children who have received 4 doses of the company’s Pentacel vaccine, and its DAPTACEL vaccine for diphtheria, or have received both.

Quadrecel’s approval was based on the results of a phase 3 study, which demonstrated that Quadracel has a similar safety and immunogenicity profile as the DTaP vaccine and IPV when administered separately.

The vaccine carries a small risk of allergic reactions, the company said, and may not protect all children receiving the vaccine.

Side effects possible include pain, redness, swelling at the injection site, muscle pain, fatigue and headaches.

Related Videos
Aaron Henry, PA-C, MSHS: Regaining Black Male Patient Trust in the Doctor's Office
Danielle O'Laughlin, PA-C, MS: Navigating Long-Term Risks, Family Planning in PCOS
Addressing HS Risks at the Genetic Level, with Kai Li, BSc
Maternal Hidradenitits Suppurativa Linked to Neonatal Mortality, Pediatric Hospitalization Risk
Nanette B. Silverberg, MD: Uncovering Molluscum Epidemiology
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
A Year of RSV Highs and Lows, with Tina Tan, MD
Gestational Low-Dose Aspirin Does Not Increase Risk of IBD Flares in Women
Ryan A. Smith, MD: RSV Risk in Patients with IBD
Riha Bhatt, MD: Mimickers and Concurrent Diseases in Pediatric IBD
© 2024 MJH Life Sciences

All rights reserved.